The collection of proprietary Chinese medicines is frequent, and the market "shuffle" may speed up

Since the reform of centralized drug procurement in 2018, in fact, no Chinese patent medicine has been included in large-scale centralized procurement
.
In this regard, the industry believes that this is mainly due to various reasons such as the inability to conduct consistent evaluation and the inability to simply determine the quality and efficacy
.
However, it is worth noting that, judging from the 19 provinces, autonomous regions and municipalities led by Hubei Province some time ago, the 19 provinces, autonomous regions and municipalities in the alliance opened bids for the centralized procurement of Chinese patent medicines, and the average price dropped by 42.
27%.
It has been fully integrated into centralized procurement or has begun to speed up
.
It is understood that on December 21, the 19-province alliance opened bids for the centralized procurement of proprietary Chinese medicines
.
Hubei took the lead in Hebei, Shanxi and other 19 provinces and cities to form an inter-provincial centralized procurement alliance for Chinese patent medicines, and jointly launched the centralized procurement of Chinese patent medicines in Wuhan
.
Through on-site competition, 97 companies and 111 products were selected, with a selection rate of 62%, an average drop of 42.
27%, and the highest drop of 82.
63%
.
On the whole, the products selected for the centralized procurement of Chinese patent medicines have complete dosage forms and specifications, and at the same time cover some of the drugs recommended by the eighth edition of the national diagnosis and treatment plan
.
In addition, mainstream Chinese patent medicine products such as Shuanghuanglian Oral Liquid and recommended drugs such as Shenmai Injection were also selected
.
According to the annual demand measurement of the 19-province alliance, the industry expects to save more than 2.
6 billion yuan in drug costs each year
.
In addition to the inter-provincial centralized procurement alliance of Chinese patent medicines launched in Hubei Province, in fact, many places opened the curtain of centralized procurement of Chinese patent medicines last year
.
For example, on September 19, Guangdong announced the launch of centralized procurement of Chinese patent medicines in 7 provinces
.
On September 14, the Guangdong Provincial Drug Trading Center released the "Guangdong Alliance Qingkailing and other 58 Pharmaceutical Groups Procurement Documents with Volume (Draft for Comment)".
.
.
On the whole, the objects of centralized procurement are mainly some with large demand and amount of money.
High-quality Chinese patent medicine varieties; the effect of centralized procurement is better, and the decline of Chinese patent medicines winning the bid is generally larger
.
The analysis believes that with the development of local pilots for the centralized procurement of Chinese patent medicines in various regions and the advancement of various medical reform policies, the pace of centralized procurement of Chinese patent medicines will continue to accelerate.

.
It is worth mentioning that, because the national centralized procurement of Chinese patent medicines and the inter-provincial alliance centralized procurement of Chinese patent medicines in China aim to win the bidding of Chinese patent medicines with higher "cost-effectiveness"
.
Therefore, for the winning pharmaceutical companies, the centralized procurement policy of proprietary Chinese medicines will still be a favorable policy.
Although the price will drop significantly, the expansion of the market scale will also make up for a certain profit loss
.
However, it should be noted that, at the same time, a major market reshuffle will follow, and some traditional Chinese medicine companies without core competitiveness may be accelerated by the times
.
In this context, the industry suggests that Chinese patent medicine-related companies can try to increase investment in research and development, build standardized planting bases for Chinese medicinal materials, improve quality standards, and set up professional-level academic self-support promotion teams to meet the challenges
.
It is reported that China Resources Sanjiu said in its reply to investors earlier that it is studying the plan based on its own product conditions, and will pay attention to and formulate corresponding plans based on product grouping, application volume, and manufacturer competition
.